Downregulation of both mRNA and protein levels of SLC17A7 was observed in tumor cells compared to normal brain tissues, and it was suggested that cancer cells take advantage of bivalency to silence this gene, preventing its tumor-suppressive activity (Figure 2). Here, SLC17A7 is linked to neoplasm.